Two complete response letters from the US Food and Drug Administration were revealed in the waning days of November. Interestingly, both CRLs went to products holding breakthrough therapy designations in the same general field of supportive care for patients undergoing chemotherapy.
BeyondSpring Inc.’s plinabulin and Fennec Pharmaceuticals Inc.’s Pedmark are the latest members of a small group that has been expanding in the last two years: BTD products with CRLs
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?